利基控股(00240.HK)上半年純利1.99億港元 同比增長35.16%
格隆匯8月24日丨利基控股(00240.HK)發佈公吿,截至2022年6月30日止六個月,集團的營業額及除税後溢利分別增加25%及33%。由於去年手上尚未完成的工程數目呈上升趨勢,故截至上半年度的營業額維持升勢,由2021年的47億港元增加至2022年的58億港元。營業額的增長率實際低於預算,概因第五波新型冠狀病毒疫情令多個建築地盤須於2022年上半年間歇關閉。隨着疫情趨於穩定,以及於2021年年底取得的多個大型新項目順利啟動,管理層相信2022年全年度的營業額必將超越去年。公司擁有人應占溢利1.99億港元,同比增長35.16%,基本每股盈利16.0港仙。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.